{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-23-000049","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.245466+00:00","generated_at":"2026-06-12T09:46:09.442592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q2 2023: Revenue up 6% to $7.0B; Non-GAAP EPS rises 8% to $5.00","bullets":["Total revenues increased 6% to $7.0B; product sales volume growth of 11% partially offset by FX and price.","GAAP EPS $2.57 (up 5% YoY); Non-GAAP EPS $5.00 (up 8% YoY), driven by record revenues.","Free cash flow $3.8B vs $1.7B in Q2 2022, due to timing of tax payments and higher income.","Pipeline: positive top-line for tarlatamab in small cell lung cancer and LUMAKRAS+Vectibix in colorectal cancer.","Volume growth double-digit for EVENITY, BLINCYTO, Repatha, LUMAKRAS, Vectibix, KYPROLIS, Nplate, AMJEVITA."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-23-000049","json":"https://secwatch.observer/filing/0000318154-23-000049.json","markdown":"https://secwatch.observer/filing/0000318154-23-000049.md","text":"https://secwatch.observer/filing/0000318154-23-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/0000318154-23-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/amgn-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:46:09.442592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4e9881a8f71d21da2ee3eef080f4eba6bb31efb","claim":"AMGEN INC reported the second quarter of 2023 results: revenue $7.0 billion, EPS $5.00.","evidence_excerpt":"shared today illustrates the rapid progress we are making in advancing our pipeline of potential first-in-class medicines.\" Key results include: • Total revenues increased 6% to $7.0 billion in comparison to the second quarter of 2022, resulting from a 6% increase in product sales. Produ ct sales growth was driven by 11% volume growth, partially offset by 2% lower","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/0000318154-23-000049-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$7.0 billion"},{"label":"EPS","value":"$5.00"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}